Nrf2 expression is associated with poor outcome in osteosarcoma

Pathology

Volumn 44, Issue 7, 2012, Pages 617-621

  Park, Jae Young ^a   Kim, Youn Wha ^a   Park, Yong Koo ^a  

^a Kyung Hee University College of Medicine   (South Korea)

Author keywords

Immunohistochemistry; NF E2 related factor 2; Osteosarcoma; Prognosis

Indexed keywords

NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CHILD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; OSTEOSARCOMA; PATHOLOGY; PROGNOSIS; SOUTH KOREA; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OSTEOSARCOMA; PROGNOSIS; REPUBLIC OF KOREA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872971814     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328359d54b     Document Type: Article

References (41)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75: 203-10.
2. Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 2005; 41: 2836-45.
3. Bielack S, Jurgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res 2009; 152: 289-308.
4. Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994; 91: 9926-30.
5. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 2009; 48: 91-104.
6. Niture SK, Kaspar JW, Shen J, et al. Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 2010; 244: 37-42.
7. Zhang Q, Pi J, Woods CG, et al. A systems biology perspective on Nrf2- mediated antioxidant response. Toxicol Appl Pharmacol 2010; 244: 84-97.
8. Cho HY, Jedlicka AE, Reddy SP, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002; 26: 175- 82.
9. Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocininduced diabetic nephropathy. Diabetes 2010; 59: 850-60.
10. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
11. Rangasamy T, Guo J, Mitzner WA, et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005; 202: 47-59.
12. Yu X, Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat Res 2005; 591: 93-102.
13. Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004; 64: 6424-31.
14. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Neh2 domain. Genes Dev 1999; 13: 76-86.
15. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130-9.
16. Lau A, Villeneuve NF, Sun Z, et al. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58: 262-70.
17. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008; 29: 1235-43.
18. Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006; 28: 813-8.
19. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008; 105: 13568-73.
20. Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135: 1358-68.
21. Jiang T, Chen N, Zhao F, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010; 70: 5486-96.
22. Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-like ECHassociated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010; 9: 336-46.
23. Kim YR, Oh JE, Kim MS, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010; 220: 446-51.
24. Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007; 362: 816-21.
25. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006; 21: 689-700.
26. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1- NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3: e420.
27. Cho JM, Manandhar S, Lee HR, et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 2008; 260: 96-108.
28. Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49: 1603-16.
29. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008; 68: 7975-84.
30. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. (German.). Pathologe 1983; 4: 135-41.
31. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248-59.
32. Thimmulappa RK, Mai KH, Srisuma S, et al. Identification of Nrf2- regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196-203.
33. Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-45.
34. Wang J, Zhang M, Zhang L, et al. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J Surg Res 2010; 164: e99-105.
35. Yang H, Wang W, Zhang Y, et al. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer 2011; 12: 166-71.
36. Konstantinopoulos PA, Spentzos D, Fountzilas E, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011; 71: 5081-9.
37. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors.World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002; 264-270.
38. Matsuno T, Okada K, Knuutila S. Telangiectatic osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002; 271-272.
39. Bispo RZ Jr, Camargo OP. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo) 2009; 64: 1177-86.
40. Raffo A, Lai JC, Stein CA, et al. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004; 10: 3195-206.
41. Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423-32.